Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica FE DE ERRORES
Journal Information
Vol. 26. Issue 9.
Pages 603 (November 2008)
Share
Share
Download PDF
More article options
Vol. 26. Issue 9.
Pages 603 (November 2008)
FE DE ERRORES
Full text access
FE DE ERRORES
Visits
3193
This item has received
Article information
Full Text

Introduction

Ferran Navarro and Jesús Rodríguez-Baño Enferm Infecc Microbiol Clin. 2007;25 Supl 2:1 Conflict of interest: Ferran Navarro declares he has no conflict of interest. Jesús Rodríguez-Baño declares he has been a scientific advisor and speaker for MSD, Wyeth, Roche and Pfizer.

Evolution and current situation of ESBL

Rafael Cantón, Aránzazu Valverde, Ángela Novais, Fernando Baquero and Teresa Coque Enferm Infecc Microbiol Clin. 2007;25 Supl 2:2-10 Conflict of interest: the authors declare they have no conflict of interest.

The genetic environment of ESBL: implications in transmission

Ferran Navarro and Elisenda Miró Enferm Infecc Microbiol Clin. 2007;25 Supl 2:11-7 Conflict of interest: the authors declare they have no conflict of interest.

Epidemiology and control of nosocomial ESBL-producing microorganisms

Carmen Peña and Miquel Pujol Enferm Infecc Microbiol Clin. 2007;25 Supl 2:18-22 Conflict of interest: the authors declare they have no conflict of interest.

Epidemiology of ESBL in the community. An increasing problem

Lorena López-Cerero and Alvaro Pascual Enferm Infecc Microbiol Clin. 2007;25 Supl 2:23-8 Conflict of interest: Lorena López Cerero declares she has no conflict of interest. Álvaro Pascual declares he has been a speaker in a symposium organized by AstraZeneca.

ESBL in animals and their importance in transmission to humans

Carmen Torres and Myriam Zarazaga Enferm Infecc Microbiol Clin. 2007;25 Supl 2:29-37 Conflict of interest: the authors declare they have no conflict of interest.

Association of ESBL with other resistance mechanisms

Luis Martínez-Martínez Enferm Infecc Microbiol Clin. 2007;25 Supl 2:38-47 Conflict of interest: the author declares he has been a consultant for Wyeth, participated in conferences sponsored by Chiron, Wyeth and GSK, and has received research funds from Chiron, Wyeth, GSK, MSD and Pfizer.

Importance of ESBL in the prognosis and cost of infections

José Miguel Cisneros and Elisa Cordero Enferm Infecc Microbiol Clin. 2007;25 Supl 2:48-53 Conflict of interest: the authors declare they have no conflict of interest.

Impact of ESBL on empirical therapy and antibiotic policies

Jesús Rodríguez-Baño and María Dolores Navarro Enferm Infecc Microbiol Clin. 2007;25 Supl 2:54-9 Conflict of interest: Jesús Rodríguez-Baño declares he has been a scientific advisor and speaker for MSD, Wyeth, Roche and Pfizer. María Dolores Navarro declares she has no conflict of interest.

Treatment of ESBL producers

David L. Paterson Enferm Infecc Microbiol Clin. 2007;25 Supl 2:60-3 Conflict of interest: the author has grants from the Centers for Disease Control and Prevention, National Institutes of Health and AstraZeneca Pharmaceuticals. He has been a consultant to the following companies: Acureon, Merck, Protez, AstraZeneca, Elan, Johnson and Johnson, and Rib-X.

Copyright © 2008. Elsevier España, S.L.. Todos los derechos reservados
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos